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Four guanidino compounds that have been found to be markedly increased in cerebrospinal fluid and brain tissue of 
uremic patients, namely, guanidine, methylguanidine, creatinine, and guanidinosuccinic acid, were applied to mouse 
spinal cord neurons in primary dissociated cell culture to evaluate their effects on postsynaptic responses to gamma- 
aminobutyric acid (GABA) and glycine. Intracellular microelectrode recording techniques were used. Guanidine, 
methylguanidine, creatinine, and guanidinosuccinic acid reversibly and in a dose-dependent manner inhibited both 
GABA and glycine responses. Guanidinosuccinic acid was the most potent inhibitor of the amino acid responses, 
followed in decreasing potency by methylguanidine, guanidine, and creatinine. Guanidinosuccinic acid inhibited 
responses to GABA and glycine, at concentrations similar to those found in cerebrospinal fluid and brain tissue of 
patients with terminal renal insufficiency. The other guanidino compounds tested exerted their effects only at concen- 
trations higher than those found in uremic biological fluids and tissues. The inhibitory effect of guanidine and 
methylguanidine on responses to GABA was additive. The effect of the guanidino compounds on GABA responses was 
not antagonized by coapplication of the benzodiazepine-receptor antagonist CGS 9896. The results suggest that 
guanidine, methylguanidine, creatinine, and guanidinosuccinic acid inhibited responses to the inhibitory neurotrans- 
mitters GABA and glycine by blocking the chloride channel. The observed action of the studied guanidino com- 
pounds might contribute to the pathogenesis of the complex neurological symptomatology encountered in uremia. 
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Patients with renal failure develop a variety of neuro- 
logical symptoms and signs. Frequent neurological 
complications of uremia include encephalopathy, poly- 
neuropathy, and epilepsy 11-31. A number of abnor- 
mal movements, including muscle fasciculations, as- 
terixis, and myoclonus, may occur in association with 
varying degrees of encephalopathy in patients with 
acute renal failure [ l ,  4 ,  51. The basis for the majority 
of the neurological complications is uncertain, and the 
pathophysiological mechanisms still remain to be eluci- 
dated. 
Guanidino compounds have been implicated as 
uremic toxins since they were found to be increased in 
uremic biological fluids [6-101 and brain 1111 and 
were demonstrated to induce toxic effects. Guanidino- 
succinic acid is suggested to be related to the uremic 
bleeding diathesis [12, 131 and has been shown to 
decrease erythrocyte transketolase activity [141. Meth- 
ylguanidine could be related to the uremic polyneu- 
ropathy [l5] and has been shown experimentally to 
induce epilepsy [l61 and a syndrome similar to the 
uremic twitch-convulsive syndrome [ 15, 17). When 
injected intracisternally, methylguanidine, taurocya- 
mine, homoarginine, creatine, and creatinine were 
found to have a convulsive effect in animals 118-22). 
Applied on the sensorimotor cortex in rabbit, a-keto- 
6-guanidinovaletic acid induced electroencephalo- 
graphic epileptiform discharges 1231. Furthermore, meth- 
ylguanidine inhibited brain sodium-potassium ATPase 
124, 251. 
In patients with severe renal insufficiency, the levels 
of guanidinosuccinic acid, creatinine, guanidine, and 
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methylguanidine in serum as well as in cerebrospinal 
fluid were found to be at least ten times higher than in 
control subjects [lo]. The same guanidino compounds 
were found to be increased from 5- to 100-fold in 
different brain regions of uremic subjects Ell). The 
experimentally observed toxicity of these guanidino 
compounds might contribute to the neurological 
symptomatology presenting in uremia. A reduction in 
gamma-aminobutyric acid (GABA)ergic inhibition in 
the central nervous system has been suggested to be a 
cause of epilepsy E26-29). A series of convulsants 
have been shown to inhibit responses to iontophoretic- 
ally applied GABA on mammalian spinal cord neurons 
grown in cell culture [30, 31). Strychnine has been 
suggested to induce myoclonus, and at high concentra- 
tions convulsions, by blocking the synaptic action of 
the inhibitory amino acid transmitter glycine (GLY) 
[32], by interacting with the postsynaptic GLY recep- 
tor 13 31. Furthermore, penicillin, known to inhibit 
GABA responses through an interaction with the 
GABA-receptor complex, induced spinal myoclonus 
after focal application in a spinal preparation in cat 
[341. 
To determine the mechanisms through which gua- 
nidinosuccinic acid, creatinine, guanidine, and methyl- 
guanidine might produce seizures and myoclonus in 
uremia, we evaluated the effects of these guanidino 
compounds on responses evoked by iontophoretically 
applied GABA and GLY recorded from spinal cord 
neurons in cell culture. 
Materials and Methods 
Primary Dissociated Cell Culture 
Cultures of spinal cord neurons were prepared from dis- 
sected spinal cords and attached dorsal root ganglia from 12- 
to 14-day-old fetal mice as described previously 1351. Experi- 
ments conformed to the policy of the American Physiology 
Society. The tissue was minced and then mechanically dis- 
sociated by trituration in Cat +-  and Mg+ +-free balanced salt 
solution to a suspension of single cells and small clumps. The 
dissociated cells were suspended in culture medium (90% 
Eagle’s minimal essential medium supplemented with 5.5 gm 
of glucose and 1.5 gm of sodium bicarbonate (NaHC03)/1, 
5% heat-inactivated horse serum, and 5% Nu-Serum I1 
[Collaborative Research, Inc.], 325 mOsmol) and then 
plated on sterile collagen-coated 35-mm dishes. The cultures 
were maintained in an incubator with an atmosphere of 93% 
room air and 7% carbon dioxide (COz) at 35°C. The bicar- 
bonate/C02 buffer maintained the p H  at 7.4. On days 4 to 6 ,  
5-fluoro-2’deoxyuridine was added to the cultures to sup- 
press the growth of rapidly dividing nonneuronal cells. Cul- 
tures were maintained for 4 to 7 weeks before electrophysio- 
logical experiments were performed. 
Experimental Procedures 
SOLUTIONS. All recordings were made in Dulbecco’s phos- 
phate-buffered saline (DPBS) solution with a high mag- 
nesium-ion concentration after removal of growth medium. 
The elevated magnesium concentration in the recording so- 
lution suppressed spontaneous synaptic and action potentials. 
The recording solution contained in mM: sodium chloride 
(NaCI), 137; sodium phosphate, dibasic (Na*HP04), 8.06; 
potassium chloride (KCI), 2.68; potassium phosphate, mono- 
basic (KH2P04), 1.47; calcium chloride (CaCIz), 1, mag- 
nesium chloride (MgCL), 10; and glucose, 5.6 (pH 7.4). 
Heavy paraffin oil was applied to the surface of the bathing 
solution to retard evaporation. Solutions of drugs were al- 
ways prepared on the day of the experiment in the following 
manner: guanidine hydrochloride, methylguanidine hydro- 
chloride, creatinine, and guanidinosuccinic acid were dis- 
solved in DPBS to form 100 mM stock solutions. Aliquots 
were removed and diluted in bathing medium to obtain the 
applied concentrations. For the drug concentrations of 10 
mM and 20 rnM, iso-osmolar solutions were prepared by 
substituting sodium chloride with the respective guanidino 
compound. The p H  of the solutions was 7.2 to 7.4. 
Guanidine and rnethylguanidine were applied at concen- 
trations between 100 nM and 100 mM. Creatinine concen- 
trations ranged from 1 pM to 20 mM and guanidinosuccinic 
acid was tested at concentrations ranging between 10 pM 
and 100 mM. CGS 7896, a pyrazoloquinoline previously 
shown to be a pure benzodiazepine-receptor antagonist, was 
dissolved in dimethylsulfoxide to obtain a 10 mM stock solu- 
tion. Aliquots were removed and diluted in bathing medium 
to obtain the applied concentration containing less than 
0.1% dimethylsulfoxide. 
EXPERIMENTAL APPARATUS. For experiments, the culture 
dish containing bathing solution was placed on a microscope 
fitted with phase contrast optics to facilitate micropipette 
placement (using rnicromanipulators) and to penetrate cells 
under direct visual control. 
ELECTKOPHYSIOLOGICAL RECORDINGS. Intracellular re- 
cordings were made from somata of spinal cord (> 20 pn) 
neurons using glass micropipettes (25 to 50 M a )  filled with 3 
M KCI. Use of an active bridge circuit (Model 8100, Dagan 
Corporation, Minneapolis, MN) allowed simultaneous re- 
cording of membrane potential and injection of current (for 
steady-state polarization or periodic stimulation) using a sin- 
gle micropipette. The preamplifier output signal was led to a 
six-channel polygraph (Model 2600, Gould Instruments Inc., 
Cleveland, OH) for continuous recording. 
GABA AND GLYCINE RESPONSES. GABA (0.5 M, pH 3.4) 
and GLY (0.5 M, pH 3.0) were applied iontophoretically 
using 500-millisecond rectangular current pulses at 5-second 
intervals. Tips of iontophoretic pipettes were positioned to 
within 2 pm of neuronal somata. The use of 3 M KC1-filled 
micropipettes resulted in elevation of intracellular chloride 
concentration and a shift in the chloride equilibrium poten- 
tial from about - 65 mV to about - 20 mV. Under these 
conditions, an increase in chloride conductance results in an 
outward chloride current 1361 giving depolarizing GABA 
and GLY responses {36, 371. Responses of about 10 to 1 5  
mV in amplitude were evoked following membrane hyper- 
polarization to between 80 mV and 90 mV. Effects on 
GABA and GLY responses were accepted only if the re- 
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sponses returned to control amplitude within 2 minutes of 
removal of the drug-containing micropipette. 
CUANIDINE UETHYLGUANIDINE 
DRUG APPLICATION. For evaluation of drug effects on 
GABA and GLY responses, all guanidino compounds were 
applied by perfusion micropipette. A blunt tipped (10- to 
15-pm) micropipette, filled with the recording solution con- 
taining the guanidino compound, was positioned 15 to 30 
p,m from the soma of the cell under study. The open end of 
the perfusion micropipette was connected to a pressure regu- 
lator, set between 0.4 and 0.8 psi, by tight-fitting polyethyl- 
ene tubing. Pressure pulse duration, regulated by a voltage- 
activated three-way valve, was 10 seconds. Under these 
conditions, local perfusion produced no artifacts and applica- 
tion of recording solution (with or without vehicle) was virtu- 
ally free of effects. During study of the effect of coapplica- 
tion of the guanidino compounds and the benzodiazepine- 
receptor antagonist CGS 9896 1381, the drugs were applied 
through one perfusion micropipette to avoid flow artifacts. 
The perfusion micropipettes were held by Leitz micromanip- 
ulators. To  decrease leakage of drugs into the bathing rne- 
dium, the tips of the perfusion micropipettes were kept in 
the oil phase between drug application trials. 
Drugs 
GABA and the guanidino compounds guanidine, methyl- 
guanidine, creatinine, and guanidinosuccinic acid (Fig 1) 
were purchased from Sigma Chemical (St. Louis, MO). CGS 
9896 (2-(p-chlorophenyl)-2,5-dihydropyrazolo)4,3-C(quino- 
lin-3(5H)-one) was obtained from Ciba-Geigy (Summit, NJ). 
Algebraic and Statistical Methods 
At all applied concentrations, mean values and standard devi- 
ations were calculated for the effects on GABA and GLY 
responses. All effects were expressed as percent change from 
control GABA response. The statistical significance of dif- 
ferences between GABA and GLY responses with and with- 
out drug application was calculated using the two-tailed Stu- 
dent’s t test; a p value of less than 0.05 was considered 
statistically significant. 
Results 
Direct Effects of Guanidine, Methylguanidine, 
Creatinine, Guanidinosuccinic Acid and CGS 9896 on 
GABA Responses 
Application of the studied guanidino compounds at 
concentrations ranging from 100 nM to 20 mM to 
spinal cord neurons did not alter resting membrane 
potential or conductance. Guanidine and methyl- 
guanidine, applied at a concentration of 100 mM, in- 
duced a membrane depolarization of 10 to 25 mV. 
Application of recording solution (n = 16) did not 
significantly alter GABA responses (0.1 k 1.7%). 
Application of CGS 9896 1 pM (n = 11) did not 
result in significant effects on GABA responses (0.23 
k 4.36% increase). Guanidine, methylguanidine, cre- 
atinine, and guanidinosuccinic acid rapidly and revers- 
ibly reduced GABA responses (Fig 2). The guanidino 
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Fig 2. Reversible, concentration-dependnt effects of guanidine 
(A), methylguanidine (B), creatinine (C), and guanzdinosac- 
c h i c  acid (0) on GABA responses on spinal cord neurom in 
primary dissociated cell culture. PRE shows stable GABA re- 
sponses btfore drug application. The four middle responses show 
the effect ofthe guanidino compound. GABA responses returned 
t o  control values (POST) within 2 minutes following removal of 
the guanidino compound-containing micropi$ette. Iontopboretic 
appiication of GABA is indicated with a d a h  
compound-induced effects were concentration depen- 
dent (Fig 3). A significant 23.9 * 8.45% decrease (p 
< 0.01) (n = 10) of GABA responses was obtained 
with 10 mM guanidine and complete inhibition was 
observed with 100 mM (n = 5). A significant decrease 
of 34.7 * 14.5% (p < 0.001) (n = 16) was obtained 
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Guanidino Compound Conc Log (M) 
Fig 3. Concentration-dependent change of GABA responses in 
spinal cord neurons by guanidine (black circles), methylguani- 
dine (white circles), creatinine (black triangles), and guani- 
dinosuccinic acid (white triangles). Effects are expressed in per- 
cent decrease of the original GABA response. Data shown are 
mean values and standard deviations. Four to sixteen cells were 
studied for each concentration tested. Asterisk indicates p < 
0.01, double asterisk, p < 0.001 from control GABA response. 
Guanidino compound concentrations on the abscissa are loga- 
rithm molar. 
at 10 mM methylguanidine and a total reduction of 
GABA responses was observed at 100 mM methyl- 
guanidine (n = 5). Creatinine was devoid of any 
significant effect on GABA responses at concentra- 
tions up to 10 mM. At 20 mM, however, creatinine 
significantly reduced GABA responses by 23.5 t 
7.55% (p < 0.01) (n = 9). The weak inhibition of 
GABA responses (3.72 & 4.76%) (n = 6) by guani- 
dinosuccinic acid applied at 10 pM was not statistically 
significant. However, a significant 12.1 & 3.69% gua- 
nidinosuccinic acid-induced decrease (p < 0.01) (n = 
6) of GABA responses was obtained at 100 pM and 
an almost complete inhibition of GABA responses 
(85.9 t 13.5%) (n = 5) was observed at 10 mM. 
Guanidinosuccinic acid was approximately ten times 
more potent than guanidine and methylguanidine in 
inhibiting GABA responses. 
Direct Effects of Guanidine, Metbylguanidine, 
Creatinine, and Guanidinosuccinic Acid on 
Glycine Responses 
Guanidine (10 mM), methylguanidine (10 mM), creati- 
nine (20 mM), and guanidinosuccinic acid (100 pM 
and 10 mM) rapidly and reversibly decreased GLY 
responses in a statistically significant manner (p < 
0.01) (Fig 4, Table 1). The guanidino compounds were 
equally potent in decreasing GLY and GABA re- 
sponses. 
Fig 4. Reversible effects of (A) guanidine (G) (1 0 mM), (Bj 
methylguanidine (MG) (1 0 mM), (C) creatinine (CTN) (1 0 
mMj, and (0) guanidinosuccinic acid (GSA) (I 0 mMj on gly- 
cine responses on spinal cord neurons. PRE shows stable glycine 
responses before drug appbcation. The mzda'k response shows the 
ejjjct ofthe miniperjked drug. Glycine responses returned to con- 
trol zialues (POST) within 2 minutes following removal of the 
guanidino compound-containing micropipette. Iontopboretic ap- 
plication of glycine is indicated with a Ash. 
Table I .  Effects of Guanidine, Methylguanidine, Creatinine, 
and Guanidinosuccinic Acid on Glycine (GLY) 
Responses on Mouse Spinal Cord Neurons 
No. of GLY Responses 
Cells o/o Decrease 
Studied (Mean f SD) 
Guanidine 10mM 5 28.1 i- 6.31" 
Methylguanidine 10 mM 5 28.1 * 8.52" 
20mM 6 31.0 ? 7.77" 
Creatinine 1omM 5 1.86 * 2.68 
100kM 4 14.8 5 6.00" Guanidino- 
succinic acid 10 m~ 9 96.6 * 6.45" 
"p < 0.01, from control, Student's two-tailed t test. 
Efects of Coapplication of Guanidine, Metbylguanidine, 
Creatinine, and Guanidinosuccinic Acid with CGS 
9896 on GABA Responses 
The effects on GABA responses of guanidine (10 
mM), methylguanidine (10 mM), creatinine (20 mM), 
and guanidinosuccinic acid (10 mM) alone or in combi- 
nation with CGS 9896 (1 pM), a pure benzodiazepine- 
receptor antagonist, were not significantly different 
(Table 2). 
Additive EHects of Guanidine and Metbylguanidine on 
GABA Responses 
Coapplication of methylguanidine (10 mM) and guani- 
dine (10 mM) resulted in a significantly larger inhibi- 
tion of GABA responses than when either of these 
compounds were applied alone at 10 mM. Whereas 
methylguanidine (10 mM) reduced GABA responses 
25.7 f 7.37% (n = 3) and guanidine (10 mM) re- 
duced GABA responses 23.3 * 4.1% (n = 3), their 
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Table 2. Effect of CGS 9896, Guanidine, Metbylguanidine, Creatinine, 
and Guanidinosuccinic Acid on G A B A  Responses on Monse Spinal Cord 
GABA Responses 
% Decrease 
(Mean ? SDj No. of Cells Studied" 
~ 
CGS 9896 (1 pM) 
Guanidine (10 mM) 
Guanidine (10 mM) + CGS 9896 ( I  kM) 
Methylguanidine (10 mM) 
Methylguanidine (10 mM) + CGS 9896 (1 pMj 
Creatinine (20 mM) 
Creatinine (20 mM) + CGS 9896 (1 pM) 
Guanidinosuccinic acid (10 mM) 










0.23 i. 4.36 
24.9 t 0.75 
24.3 & 9.10 
28.5 ? 3.69 
32.2 k 6.74 
21.0 k 5.81 
21.1 -c 7.39 
94.7 * 9.12 
93.3 5 11.5 
coapplication resulted in a 39.7 ? 7.93% (n = 3) 
decrease of GABA responses. 
Discussion 
A variety of convulsants have been shown previously 
to inhibit GABAergic inhibition [37, 39-4 1) through 
interaction with the postsynaptic GABA-receptor 
complex consisting of a functionally coupled benzodia- 
zepine receptor, GABA receptor, and chloride chan- 
nel 142, 43). Several convulsants reduced responses to 
iontophoretically applied GABA on mouse neurons 
grown in cell culture. DMCM, a convulsant beta- 
carboline, and CGS 8216, a pyrazolo-quinoline with 
proconvulsant effect, inhibited GABA responses [38, 
41, 44, 451 through an interaction with the ben- 
zodiazepine receptor. Moreover, the convulsants bicu- 
culline, picrotoxin, and pentylenetetrazole were 
previously reported to selectively antagonize GABA- 
mediated postsynaptic inhibition in cultured mamma- 
lian neurons [37, 39, 41, 451. Penicillin, a convulsant 
that is known to induce myoclonus after intravenous 
administration in humans 1461 and focal application in 
cat, 1341 also antagonized GABA responses on mouse 
neurons 1391. Strychnine, inducing myoclonus at low 
doses and convulsions at higher concentrations, has 
been shown previously to be a GLY-receptor antago- 
nist 133). 
In this study, we investigated the effects of four 
guanidino compounds, which were found to be in- 
creased in cerebrospinal fluid and brain of uremic pa- 
tients { 103, on responses to the iontophoretically ap- 
plied inhibitory neurotransmitters GABA and GLY 
on mouse neurons in primary dissociated cell culture. 
The guanidino compounds were guanidine, methyl- 
guanidine, creatinine, and guanidinosuccinic acid. 
Guanidine, methylguanidine, creatinine, and guani- 
dinosuccinic acid inhibited both GABA and GLY re- 
sponses on mouse spinal cord neurons in culture in a 
concentration-dependent manner. Guanidinosuccinic 
acid was the most potent compound, followed by 
methylguanidine, guanidine, and creatinine. Guanidi- 
nosuccinic acid inhibited GABA and GLY responses 
at concentrations similar to those found in cerebrospi- 
nal fluid (up to 32 pM) and brain tissue (up to 21 
nmoVgm of tissue) of patients with terminal renal 
insufficiency. The studied guanidino compounds did 
not reduce GABA responses chrough an interaction 
with the benzodiazepine receptor. Indeed, CGS 9896, 
a pyrazoloquinoline and pure benzodiazepine-receptor 
antagonist {38],  did not antagonize the guanidino com- 
pound-induced inhibition of GABA responses. Ear- 
lier studies on cultured neurons demonstrated that the 
inhibitory neurotransmitters GABA and GLY act 
through different receptors on the membrane surface 
[30, 47, 481. Moreover, activation of chloride conduc- 
tance has been demonstrated to underlie the GABA- 
and GLY-receptor-coupled events [49). Since GABA 
and GLY exert their inhibitory effects by activation of 
chloride conductance through interaction with differ- 
ent receptors, our observations suggest that guanidine, 
methylguamdine, and guanidinosuccinic acid, shown 
here not to be benzodiazepine-receptor ligands, inhibit 
inhibitory amino acid-responses by blocking chloride 
channels. 
Structure-activity relationships cannot be established 
from the data presented in this report. Creatinine, the 
anhydrized form of creatine, was the least potent in 
decreasing responses to GABA and GLY, whereas the 
monosubstituted guanidino compounds guanidinosuc- 
cinic acid and methylguanidine were more potent than 
guanidine. Previous reports demonstrated that the po- 
tency of N-alkyl-guanidino compounds in blocking 
ionic channels of the motor end-plate membrane was a 
function of the length of the alkyl side chain [ S O ] .  It 
was suggested that the blochng potency, enhanced by 
~ 
"Vertical lines indicate paired samples. No significant differences were found (Student's t test for paired samples). 
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lengthening the side chain, might be related to the 
increase in side chain hydrophobicity. 
The observed inhibitory effects of guanidine, meth- 
ylguanidine, creatinine, and guanidinosuccinic acid on 
inhibitory neurotransmitter responses might have 
pathophysiological implications in uremia. Indeed, 
guanidinosuccinic acid displayed significant effects on 
GABA and GLY responses at concentrations sim- 
ilar to those found in cerebrospinal fluid and brain 
tissue of uremic patients [lo, 111. Moreover, guani- 
dine, methylguanidine, and creatinine, which reduced 
GABA and GLY responses only at concentrations 
higher than those hitherto found in cerebrospinal Huid 
of uremic patients, might have, perhaps in combination 
with still other toxins, additive effects. The additive 
inhibitory effect of guanidine and methylguanidine on 
responses to GABA has been demonstrated in this 
report. A summative effect has also been shown for 
creatinine, creatine, guanidinoacetic acid, and guani- 
dine in an experimental paradigm testing in vitro auto- 
hemolysis [24}. Earlier reports demonstrated methyl- 
guanidine [ l G }  to be more potent than creatinine { 2 O )  
in inducing seizures in rabbit after intracisternal admin- 
istration. This is in agreement with the higher potency 
of methylguanidine in decreasing responses to inhibi- 
tory neurotransmitters as illustrated in this report. The 
in vivo epileptogenicity of guanidine and guanidino- 
succinic acid has not been demonstrated or disproved 
as yet. 
In addition to reducing GABA and GLY responses, 
other postsynaptic and presynaptic effects have been 
shown for guanidino compounds in the peripheral as 
well as in the central nervous system. Guanidine has 
been shown to increase transmitter release at the frog, 
rat, and crayfish neuromuscular junctions I5 1-54] and 
in the guinea pig olfactory cortex [55] .  In addition, 
methylguanidine inhibited responses to acetylcholine 
in frog sartorious muscle { S O ,  5 2 )  and guanidine was 
found to have a dual effect on cat spinal monosynaptic 
reflex transmission (inhibiting at low doses and en- 
hancing at high doses) [56] .  These electrophysiological 
effects and reduction of GABA and GLY responses 
by the guanidino compounds might contribute to the 
central and peripheral nervous system symptomatol- 
ogy presenting in uremia. Moreover, methylguanidine 
has been shown to inhibit brain sodium-potassium 
ATPase, an effect which could also contribute to its 
epileptogenic activity 1251. 
In conclusion, guanidine, methylguanidine, crea- 
tinine, and guanidinosuccinic acid, found to be in- 
creased in cerebrospinal fluid and brain of uremic 
patients, inhibited responses to the inhibitory neuro- 
transmitters GABA and GLY on mouse neurons in 
cell culture. Guanidinosuccinic acid inhibited GABA 
and GLY responses at concentrations similar to those 
previously found in cerebrospinal fluid and brain of 
uremic patients. The underlying mechanism is sug- 
gested to be the blocking of the chloride channel. This 
effect, alone or in combination with other effects ex- 
erted by these compounds or other toxins, might 
underlie the pathogenesis of the myoclonus, epilepsy, 
and encephalopathy presenting in uremia. 
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